Drug Discovery Technologies Market

The drug discovery technologies market is projected to reach USD 51.51 billion by 2031 from USD 30.58 billion in 2025, at a CAGR of 11.0% during the forecast period.

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), F. Hoffmann-La Roche Ltd (Switzerland), Bruker (US), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Tecan Trading AG (Switzerland), Takara Bio Inc. (Japan), Corning Incorporated (US), Hamilton Company (US), PacBio (US), Oxford Nanopore Technologies plc (UK), Promega Corporation (US), Waters Corporation (US), Merck KGAA (Germany), Sartorius AG (Germany), BD (US), Eppendorf SE (Germany), Shimadzu Corporation (Japan), Aurora Biomed Inc. (Canada), Standard BioTools (US), Jeol Ltd. (Japan), Gilson Incorporated (US), BIOMÉRIEUX (France), Greiner AG (Austria), BGI Group (China), and Porvair (UK) are the key players in this market.

To know about the assumptions considered for the study download the pdf brochure

These market players have adopted various approaches, including product launches, collaborations, acquisitions, agreements, and expansions, to enhance their market positions. In October 2025, Thermo Fisher Scientific Inc. launched the Applied Biosystems SwiftArrayStudio Microarray Analyzer, designed for sample analysis. In conjunction with two new arrays-the Applied Biosystems Axiom PharmacoPro Array and the Applied Biosystems Axiom PangenomePro Array- the analyzer combines four genotyping processes into a single, integrated device.

In May 2025, Agilent Technologies, Inc. announced the opening of its India Solution Center at its LEED Platinum-certified office in Manesar, Haryana. The facility has dedicated zones for chromatography, mass spectrometry, spectroscopy, genomics, cell analysis, and lab informatics.

Thermo Fisher Scientific Inc. (US): Thermo Fisher Scientific provides a diverse portfolio of equipment and platforms supporting drug discovery workflows. Its offerings include cell culture systems, reagents, high-content screening instruments, genomic and proteomic technologies, and data analysis software. The company supports early target identification through lead optimization. With strong integration across hardware, consumables, and informatics, Thermo Fisher enables faster research execution and scalable discovery programs for pharma and biotech customers.

Danaher Corporation (US): Danaher takes part in drug research through its Cytiva, Beckman Coulter Life Sciences, and Leica Biosystems. These companies provide core lab equipment used in early discovery work. This includes tools for sample handling, screening, imaging, and routine analysis. Researchers use them while setting up assays and running repeated tests. The focus is on making lab work smoother and repeatable, which helps research groups save time and avoid common workflow issues.

Agilent Technologies, Inc. (US): Agilent Technologies delivers analytical and bioanalytical solutions for drug discovery and development. Its portfolio includes chromatography, mass spectrometry, cell analysis, and sample preparation systems. Agilent supports compound identification, biomarker analysis, and assay validation. The company emphasizes data accuracy, instrument reliability, and workflow integration. Its solutions are widely used by pharmaceutical and biotechnology companies to improve decision-making during early-stage drug discovery.

Market Ranking

The drug discovery technologies market is moderately consolidated, with major life science technology providers shaping innovation and adoption. Leading players include Thermo, Fisher Scientific (US), Danaher Corporation (US), and Agilent Technologies (US). Thermo Fisher provides integrated platforms for cell & molecular biology, screening, genomics, and data analysis to facilitate end-to-end drug discovery & development workflows. Danaher enhances the capabilities for discovery through automation, imaging, and high-throughput systems via its life sciences subsidiaries. Agilent focuses on analytical and bioanalytical technologies, which bring certainty to compound profiling, biomarker analyses, and decisions informed by data. Together, these companies extend access to technology, enhance research productivity, and facilitate quicker, more reliable drug discovery programs.

Related Reports:

Drug Discovery Technologies Market by Product (Instruments, Reagents, Software), Technology (HTS, NGS, PCR, Al-based, Lab-on chip), Process (Target Identification, Validation, Lead Optimization), Therapeutic Area (Oncology, CVD) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com